AbbVie (ABBV) Q3 Earnings Beat Estimates on Immunology Drug Sales

AbbVie (ABBV) reported quarterly earnings that exceeded analysts' expectations, driven by sales from newer immunology drugs that compensated for the decline in Humira's revenue. The company showcased a positive trend as net revenue from immunology reached $2 billion, while Humira sales decreased by 33% to $1.5 billion. This change reflects the ongoing transition to newer therapies, which may bolster AbbVie's market position. The performance indicates potential for recovery and growth, impacting investor sentiment positively.